COVID-19 signs, symptoms and severity of disease: A clinician guide
Last updated: June 18, 2020
The information below is based on currently available scientific evidence and informed by expert opinion, and is subject to change as new information becomes available. The contents provide clinicians with interim information on what is presently known about the clinical features of COVID-19, including presentation, risk factors and the spectrum of disease severity. COVID-19 is the disease caused by SARS-CoV-2 coronavirus, a new virus that was first recognized in Wuhan, China, in December 2019.
Signs and symptoms
COVID-19 presents with varied clinical features. Clinical presentation and symptoms of COVID-19 vary in frequency and severity. Common reported symptoms may be broadly categorized as “more frequent”, “less frequent” and “rare” (Table 1) Footnote 1Footnote 2Footnote 3Footnote 4Footnote 5Footnote 6Footnote 7Footnote 8Footnote 9Footnote 10Footnote 11Footnote 12Footnote 13Footnote 14. The true frequency of symptoms associated with COVID-19 is unknown. Published reports may over-represent individuals who have more bothersome or severe symptoms, and this may also differ across care settings. Symptoms absent at the onset of illness may develop over time with disease progression. To date, there is no list of symptoms that has been validated to have high specificity or sensitivity for COVID-19. Clinical diagnosis should therefore always be confirmed by laboratory testing, and patients should always be encouraged to seek medical consultation if experiencing new or worsening symptoms.
|More frequent (>50%)||Less frequent (<50%)||Rare (<10%)|
Note: Symptoms among older adults (65 years of age and older) and those with underlying medical conditions may be atypical or subtle; for instance they may be more likely to present without fever or respiratory symptoms.
The frequency of fever varied among studies, ranging from 44-91%Footnote 1Footnote 2Footnote 3Footnote 4Footnote 5Footnote 6Footnote 7Footnote 8Footnote 9Footnote 10Footnote 11Footnote 12Footnote 13Footnote 14Footnote 15Footnote 16Footnote 17Footnote 18Footnote 19Footnote 20. In a large cohort study in Europe, fever was present in 45.4% of cases, while the two largest studies from China reported fever in more than 80% of patientsFootnote 29Footnote 40Footnote 41.
In many publications, fever was reported as body temperature of a minimum of 37.3 degrees Celsius and any temperature higher. In one study that reported symptoms in over 1,000 hospitalized patients, 44% of individuals were categorized as having fever on admission (22% had a body temperature between 37.6 and 38 oC, 18% between 38.1 and 39 oC, and 4% for temperatures between 38.2 – 39 oC) Footnote 1. Overall, while 89% of patients with COVID-19 in reported studies had increased body temperature during hospitalization, maximum body temperature of over 38 oC was measured in just half of the patients (38.1 – 39 oC in 47% and >39 oC in 2%) Footnote 1Footnote 2Footnote 3Footnote 4Footnote 5Footnote 6Footnote 7.
Cough, shortness of breath, fatigue, loss of appetite and loss of smell and/or taste
Other symptoms that have been commonly reported include cough, shortness of breath, fatigue, loss of appetite and loss of smell and/or taste.
Cough has been reported in many COVID-19 patientsFootnote 5Footnote 6Footnote 7Footnote 8Footnote 9Footnote 10Footnote 11Footnote 12Footnote 13Footnote 14Footnote 15Footnote 16Footnote 17Footnote 18Footnote 19Footnote 20Footnote 21Footnote 22Footnote 23Footnote 24Footnote 25Footnote 26Footnote 27Footnote 28Footnote 29Footnote 30Footnote 31Footnote 32Footnote 33Footnote 34Footnote 35Footnote 36Footnote 37Footnote 38Footnote 39. A large European study, found the frequency of cough to be 63%Footnote 2, while in two large studies from China cough was reported in 49%Footnote 20 and 66%Footnote 19of cases. In a systematic review of the literature, cough was found, on average, to be present in approximately two thirds of adult patients with non-severe diseaseFootnote 12Footnote 13. However, due to its variable frequency, cough should not be considered a sensitive indicator for COVID-19 disease.
Shortness of breath was more frequently reported in hospitalized patientsFootnote 5Footnote 6Footnote 7Footnote 8Footnote 11Footnote 19Footnote 22Footnote 26Footnote 28Footnote 29Footnote 30Footnote 31Footnote 32Footnote 33. A recent systematic review and meta-analysis, found shortness of breath present among 44% of people with severe and 6% of people with non-severe diseaseFootnote 36. Two large studies, reported shortness of breath to range from 1-8 % of mild cases, compared to 33% of severe casesFootnote 2Footnote 5.
Loss of smell and/or taste has been commonly reported (54-88%)Footnote 20Footnote 34. These symptoms may occur earlier than other symptoms, and in some cases these were the only reported manifestation of COVID-19 infection Footnote 1Footnote 2Footnote 3.
Reporting of frequency of loss of appetite (39-84%) and fatigue (31-70%) ranged widely amongst studiesFootnote 2Footnote 3Footnote 5Footnote 10Footnote 18Footnote 20Footnote 25Footnote 26Footnote 27Footnote 28Footnote 29Footnote 31Footnote 32Footnote 33Footnote 34Footnote 38Footnote 41
Other less frequent symptoms
Reports of gastrointestinal symptoms in COVID-19 patients, such as diarrhea and nausea, have ranged from 5-24% Footnote 8Footnote 9Footnote 10Footnote 11Footnote 12Footnote 13Footnote 15Footnote 39. In one publication, 19% of individuals reported these symptoms prior to the development of fever or signs of lower respiratory tract infectionFootnote 7. Other symptoms that have been less frequently reported include confusion, runny nose, fainting and skin manifestationsFootnote 10Footnote 11Footnote 12Footnote 13Footnote 14Footnote 15.
Symptoms in children
In children, the reported signs and symptoms have been similar to those observed in adults, though they may often be less severe or altogether absent. See this link for general advice on how to care for a child with COVID-19.
Reports have found fever (children 56% vs. adults 71%), cough (children 46% vs. adults 80%), and shortness of breath (children 13% vs. adults 43%) at a lower frequency in childrenFootnote 36Footnote 37Footnote 38Footnote 39Footnote 40Footnote 41. Gastrointestinal symptoms are often predominant in clinical presentation, including abdominal pain, diarrhea, nausea, and vomiting Footnote 42Footnote 43.
Clinicians should be aware of very rare complications that have been associated with COVID-19 infection. A severe multisystem inflammatory syndrome in children (MIS-C) has been reported to share features of typical or atypical Kawasaki disease or toxic shock syndromeFootnote 24Footnote 25.
The WHO preliminary case definition for MIS-C states that cases should be suspected in children and adolescents 0-19 years of age with fever for ≥ 3 days and two of the following signs or symptoms:
- rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet)
- hypotension or shock
- features of myocardial dysfunction, or pericarditis, or valvulitis, or coronary abnormalities (ECHO findings or elevated Troponin/NT-proBNP)
- evidence of coagulopathy (abnormal PT, PTT, elevated D-Dimers)
- acute gastrointestinal problems (diarrhea, vomiting or abdominal pain)
- elevated markers of inflammation such as ESR, C-reactive protein or procalcitonin
- no other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes
- evidence of COVID-19 (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID-19
Clinicians should have a high index of suspicion to obtain bloodwork for children and adolescents who present with the symptoms mentioned above.
Allergies, colds, flu and asthma during COVID-19
The most frequently reported COVID-19 symptoms (fever, cough, fatigue, loss of appetite, shortness of breath) are not specific to COVID-19 and are commonly reported in a large number of respiratory and other illnesses (e.g. common colds, influenza, asthma, and allergies). This may present increased challenges with diagnosing COVID-19 during allergy season, or when there is circulating influenza or other respiratory viruses within Canada.
Asymptomatic, pre-symptomatic and pauci-symptomatic infection
An asymptomatic person is someone with a positive SARS-CoV-2 test who never develops any symptoms, whereas a pre-symptomatic person is someone who has contracted COVID-19 and may have detectable virus, but is not yet showing symptoms. Pauci-symptomatic individuals will have a positive SARS-CoV-2 test in the presence of very limited symptomatology. Asymptomatic, pre-symptomatic and pauci-symptomatic COVID-19 cases and their exact roles in transmission is still undetermined.
Several studies have documented SARS-CoV-2 infections in patients who never develop symptoms (i.e. asymptomatic) and in patients who are not yet symptomatic (i.e. pre-symptomatic)Footnote 19Footnote 20Footnote 36Footnote 41Footnote 44Footnote 45Footnote 46Footnote 47Footnote 48Footnote 49Footnote 50Footnote 51Footnote 52. Since asymptomatic persons are not routinely tested, the prevalence of asymptomatic infection and pre-symptomatic infection are not well known. Some studies have estimated the frequency of pauci-symptomatic or asymptomatic individuals to be as high as 50% Footnote 53. It has also been shown that some presymptomatic individuals may have laboratory and radiological abnormalities prior to the onset of symptoms Footnote 20,Footnote 44,Footnote 54.
The incubation period for COVID-19 has been estimated to range from 1 to 14 days, with a median being 5-6 days from exposure to symptom onsetFootnote 1Footnote 26Footnote 27. Most individuals (97.5%) develop symptoms within 11.5 days of exposureFootnote 1Footnote 18Footnote 26Footnote 27.
Person-to-person spread via respiratory droplets is the main mode of transmission for COVID-19. With droplet transmission, infection occurs when the virus contained in the respiratory secretions of an infected person (through coughing or sneezing) reach the mucous membrane of a healthy individual. Infection can also occur if a person touches an infected surface and then touches their eyes, nose, or mouth. The contribution of surfaces or objects (also called fomites) in COVID-19 transmission is not completely understood.
The time period in which an individual with COVID-19 is infectious remains uncertain. Evidence has shown that an individual may be infectious for up to 3 days prior to any presentation of symptomsFootnote 28, which is referred to as pre-symptomatic infectiousness. The levels of viral RNA from posterior oropharyngeal saliva/sputum samples, upper respiratory specimens, and stool samples appear to be highest soon after symptom onsetFootnote 29Footnote 30Footnote 31, with some evidence that infectiousness may peak on or even before symptom onset Footnote 31Footnote 32.
Viral shedding may occur through the course of illness and the exact degree of SARS-CoV-2 viral shedding that confers risk of transmission is still unknown. A German study Footnote 35 comparing the viral loads between patients of different age groups found that viral loads in children do not differ significantly from those of adults, suggesting that children may be as infectious as adults. A Canadian study found that the SARS-CoV-2 potential to infect Vero cells under laboratory conditions was only observed at an interval between symptom onset to test of under 8 daysFootnote 55. Infectivity of patients with symptoms of ≥ 8 days is likely very low. The duration of viral shedding in severely ill patients, such as those in intensive care units or with immune suppression, is unknown but may be prolonged.
The clinical criteria for non-infectiousness, including 14 days from symptom onset or being symptoms free for 72 hours (whichever is longer) are being used in some jurisdictions. Laboratory criteria based on two negative Nasopharyngeal (NP) RT-PCR results 48 hours apart (after 14 days of symptom onset) were initially used, and are still being used in some circumstances.
Disease severity and risk factors for severe disease
The largest cohort of >44,000 adults with COVID-19 from China showed that the greatest number of cases fell into the mild-moderate category at 81%, with severe (14%) and critical (5%) disease more rare. The overall case fatality rate (CFR) that was reported in this study was 2.3%, and there was a CFR of 49% among those patients with critical diseaseFootnote 52. Among children in China, disease severity was lower with 94% having asymptomatic, mild or moderate disease, 5% having severe disease, and <1% having critical disease Footnote 21.
The Canadian Epidemiological report on June 4, 2020 estimated that 16% of Canadians diagnosed with COVID-19 have been hospitalized. Among hospitalized individuals, 20% have been admitted to the Intensive Care Unit (ICU), and 19% required mechanical ventilation. These numbers are similar to those reported by the U.S., in which the proportion of persons who were hospitalized was 19% Footnote 36.
Data have consistently shown that older adults and those with some underlying medical conditions are at highest risk for severe disease. In Canada, among hospitalized cases for whom clinical presentation was reported, 74% reported one or more pre-existing conditions. Individuals aged ≥ 60 years comprise: 68% of hospital admissions, 64% of ICU admissions and 96% of deaths. Canadian data are similar to what is seen in other countries. A summary of the most common comorbidities found in persons with COVID-19 in the literature is found in Table 2, with cardiovascular disease, hypertension and diabetes being the most common. The frequency of underlying comorbid conditions amongst severe cases of COVID-19 is much higher than that amongst non-severe COVID-19 casesFootnote 1Footnote 2Footnote 3Footnote 8Footnote 9Footnote 10Footnote 12Footnote 13Footnote 14Footnote 36Footnote 40.
|More frequent (>40%)||Less frequent (10-39%)||Infrequent (<10%)|
At the present time, it is unknown if a person can be reinfected, as well as what may be the time period between the first and subsequent infections or the potential severity of subsequent infectionsFootnote 61. Following infection, the majority of individuals will develop IgM and IgG antibodies within days to weeks of symptom onsetFootnote 58Footnote 59Footnote 60. However, the relationship between antibody levels and the level of protection against reinfection remains undetermined, as well as the role of cellular immunity in preventing reinfection (including cross-protective immunity following exposure to common coronaviruses)Footnote 58Footnote 60Footnote 61Footnote 62Footnote 63Footnote 64Footnote 65.
To date, there have been no proven cases of human reinfection with SARS-CoV-2Footnote 66. For other coronaviruses (e.g. MERS-CoV and SARS-CoV-1), protective antibodies have been reported to decline as early as several months following infectionFootnote 66.
As serological testing for the detection of SARS-CoV-2 antibodies becomes more widely available, the results are expected to provide further insight into the questions on reinfection and the duration of immunity.
As we continue to learn more about the SARS-CoV-2 virus, it is vitally important that clinicians remind Canadians to remain steadfast in preventing the spread of COVID-19. This includes following appropriate public health precautions against infections such as physical distancing, observing regular hand hygiene, respiratory etiquette, mask wearing, environmental cleaning and disinfection and self-monitoring for symptoms compatible with COVID-19.
This document was prepared by: Dr. Marianna Ofner, Dr. Dara Petel, Yung-En Chung, Dr. Oliver Baclic, Dr. Marina Salvadori, Dr. Cheryl Volling, Dr. Peter Uhthoff, Mary Lou DeCou, Aidan Pucchio and Dr. James Brooks for the COVID-19 Clinical Issues Task Group, Public Health Agency of Canada.
COVID-19 Clinical Issues Task Group, Public Health Agency of Canada, Dr. Marina Salvadori. Dr. James Brooks, Dr. Marianna Ofner, Dr. Oliver Baclic, Yung-En Chung, Mary Lou DeCou, Dr. Peter Uhthoff and Dr. Cheryl Volling.
Additional Public Health Agency of Canada resources
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic
- Infection Prevention and Control for COVID-19: Interim Guidance for Home Care Settings
- Requirements for serological antibody tests submitted under the COVID-19 Interim Order: guidance
- COVID-19 Technical Brief: Masking and face shields for full duration of shifts in acute healthcare settings
- Infection Prevention and Control for COVID-19: Second Interim Guidance for Acute Healthcare Settings
- COVID-19 Pandemic Guidance for the Health Care Sector
- Infection Prevention and Control for COVID-19: Interim Guidance for Long Term Care Homes
- Clinical Management of Patients with Moderate to Severe COVID-19 - Interim Guidance
- Interim national case definition: Coronavirus disease (COVID-19)
- Routine practices and additional precautions for preventing the transmission of infection in healthcare settings
- Interim national surveillance guidelines for human infection with coronavirus disease (COVID-19)
- Coronavirus disease (COVID-19): Summary of assumptions
- Public health management of cases and contacts associated with coronavirus disease (COVID-19)
- COVID-19 and people with disabilities in Canada
- Guidance for providers of services for people experiencing homelessness (in the context of COVID-19)
- Footnote 1
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
- Footnote 2
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 15;395(10223):507-13.
- Footnote 3
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). Lancet 2020;395(10223):497-506.
- Footnote 4
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Mar 17; 323(11): 1061-1069.
- Footnote 5
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clinical research ed). 2020;368:m606.
- Footnote 6
Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13; e200994.
- Footnote 7
Pan L, Mu M, Ren HG, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; Apr 14; 115: 10.14309/ajg.0000000000000620.
- Footnote 8
Argenziano M, Bruce S, Slater C, et al. Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. Lancet 395:507-13.
- Footnote 9
Fu, L., Bingyi, W., Yuan, T., et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020 Jun; 80(6) :656-665.
- Footnote 10
Kumar A, Arora A, Sharma P, et al. Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis. SSRN- Lancet pre-print (3/30/2020). Available at SSRN: https://ssrn.com/abstract=3566166 or http://dx.doi.org/10.2139/ssrn.3566166.
- Footnote 11
Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020 Mar 12;10.1002/jmv.25757. doi: 10.1002/jmv.25757.
- Footnote 12
Lovato, A. and C. de Filippis. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. Ear Nose Throat J, 2020: Apr 13;145561320920762.
- Footnote 13
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Inf Dis 2020 March-April; 34: 101623.
- Footnote 14
Yang J, Zheng Y, Gou X, et al. Prevalence of Comorbidities and Its Effects in Patients Infected With SARS-CoV-2: A Systematic Review and Meta-Analysis. Int J Infect Dis 2020 May; 94:91-95.
- Footnote 15
Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. J Med Virol 2020 Apr 15;10.1002/jmv.25884.
- Footnote 16
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine. 2020.
- Footnote 17
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020.
- Footnote 18
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020 Mar 10: M20-0504. Published online 2020 Mar 10. doi: 10.7326/M20-0504.
- Footnote 19
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England). 2020;395(10223):514-523.
- Footnote 20
Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. The New England journal of medicine. 2020 382:1278-1280.
- Footnote 21
Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020.
- Footnote 22
Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. The New England journal of medicine. 2020.
- Footnote 23
Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. Jama. 2020.
- Footnote 24
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet Volume 395, Issue 10239, P1771-1778, June 06, 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31103-X
- Footnote 25
Riphagen S, Gomez X, Gonzalex-Martinez et al. (May 7) Hyperinflammatory shock in children during COVID-19 pandemic Lancet, Volume 395, Issue 10237, P1607-1608, May 23, 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31094-1
- Footnote 26
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199-207.
- Footnote 27
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Diseases 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020. Volume 172, Issue 9 Page: 577-582.
- Footnote 28
Casey M, Griffin J, McAloon CG, et al. Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data. Pre-print: https://www.medrxiv.org/content/10.1101/2020.05.08.20094870v1.full.pdf
- Footnote 29
To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 2020;20(5):565-574. doi:10.1016/s1473-3099(20)30196-1.
- Footnote 30
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. 2020;382(12):1177-1179. doi:10.1056/nejmc2001737.
- Footnote 31
He X, Lau EH, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. 2020. doi:10.1101/2020.03.15.20036707.
- Footnote 32
Auwaerter PG. Coronavirus COVID-19 (SARS-CoV-2): Johns Hopkins ABX Guide. Coronavirus COVID-19 (SARS-CoV-2) | Johns Hopkins ABX Guide. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2_. Published 2020. Accessed June 14, 2020.
- Footnote 33
Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Jama. 2020;323(15):1488. doi:10.1001/jama.2020.3204.
- Footnote 34
Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x.
- Footnote 35
Jones TC, Mühlemann B, Veith T, et al. An analysis of SARS-CoV-2 viral load by patient age. 2020. doi:10.1101/2020.06.08.20125484.
- Footnote 36
Gold JA, Wong KK, Szablewskiet CM, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020. 69(18);545–550. DOI: http://dx.doi.org/10.15585/mmwr.mm6918e1
- Footnote 37
Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. Apr 30; 10.1111 / joim.13089. doi: 10.1111/joim.13089.
- Footnote 38
Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA Apr 22;323(20):2089-2090. doi: 10.1001/jama.2020.6771.
- Footnote 39
Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020 Apr 17: NEJMc2010419.
- Footnote 40
Sreenivasan J, Khan MS, Anker SD, et al. Cardiovascular Risk Factors and Complications in Patients Infected with COVID-19: A Systematic Review. 2020. Pre-prints with the Lancet: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3569855
- Footnote 41
Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. Published online April 8, 2020. doi:10.1001/jamaoto.2020.0832.
- Footnote 42
Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates. The Pediatric Infectious Disease Journal. 2020;39(6):469-477. doi:10.1097/inf.0000000000002700.
- Footnote 43
Liguoro I, Pilotto C, Bonanni M, et al. SARS-CoV-2 Infection in Children and Newborns: A Systematic Review. 2020. doi:10.21203/rs.3.rs-24629/v1.
- Footnote 44
Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Science China Life sciences. 2020.
- Footnote 45
Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. The Journal of infectious diseases. 2020.
- Footnote 46
Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. The Lancet Infectious diseases. 2020.
- Footnote 47
Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. Jama. 2020. Feb 21;323(14):1406-1407. doi: 10.1001/jama.2020.2565.
- Footnote 48
Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020 Feb 28;ciaa201. doi: 10.1093/cid/ciaa201.
- Footnote 49
McMichael TM CS, Pogosjans S, et al. COVID-19 in a Long-Term Care Facility — King County, Washington, February 27–March 9, 2020. MMWR Morbidity and mortality weekly report. 2020;69:339-342.
- Footnote 50
Kimball A HK, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020. MMWR Morbidity and mortality weekly report. 2020;ePub: 27 March 2020.
- Footnote 51
Roxby AC GA, Hatfield KM, et al. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults — Seattle, Washington, 2020. MMWR Morbidity and mortality weekly report. 2020;ePub: 3 April 2020.
- Footnote 52
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveillance: bulletin Europeen sur les maladies transmissibles - European communicable disease bulletin. 2020; 25(10).
- Footnote 53
Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of Internal Medicine. 2020. doi:10.7326/m20-3012.
- Footnote 54
Lechien, Jerome R. Clinical and Epidemiological Characteristics of 1,420 European Patients with mild‐to‐moderate Coronavirus Disease 2019. Journal of internal medicine (0954-6820) [Internet] 2020 April. [cited 2020 May 11]; DOI: https://doi.org/10.1111/joim.13089.
- Footnote 55
Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clinical Infectious Diseases, ciaa638, https://doi.org/10.1093/cid/ciaa638.
- Footnote 56
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
- Footnote 57
National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19. Supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. 11/06/20: Weekly Communique from the National Steering Committee. https://covid19evidence.net.au/.
- Footnote 58
Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. Published online March 28, 2020. doi:10.1093/cid/ciaa344PubMedGoogle Scholar.
- Footnote 59
Wölfel R , Corman VM , Guggemos W , et al. Virological assessment of hospitalized patients with COVID-2019. Nature. Published online April 1, 2020. doi:10.1038/s41586-020-2196-xPubMedGoogle Scholar.
- Footnote 60
To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574. doi:10.1016/S1473-3099(20)30196-1.
- Footnote 61
Flodgren GM. Immunity after SARS-CoV-2 infection, 1st update – a rapid review 2020. Oslo: Norwegian Institute of Public Health, 2020.
- Footnote 62
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. doi:10.1016/s0140-6736(20)30566-3.
- Footnote 63
He X, Lau EH, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. 2020. doi:10.1101/2020.03.15.20036707.
- Footnote 64
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020. doi:10.1016/j.cell.2020.05.015.
- Footnote 65
Soresina A, Moratto D, Chiarini M, et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover. Pediatric Allergy and Immunology. 2020. doi:10.1111/pai.13263.
- Footnote 66
Wu L-P , Wang N-C , Chang Y-H , et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-1564. doi:10.3201/eid1310.070576.
Report a problem or mistake on this page
- Date modified: